北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 期刊论文
学科主题: 临床医学
题名:
Improved Response Rates with Bortezomib in Relapsed or Refractory Multiple Myeloma: An Observational Study in Chinese Patients
作者: Lin, MaoFang1; Hou, Jian2; Chen, WenMing3; Huang, XiaoJun4; Liu, ZhuoGang5; Zhou, YuHong6; Li, Yan7; Zhao, Taiyun8; Wang, LinNa8; Wu, Kwang-Wei8; Shen, ZhiXiang9
关键词: Bortezomib ; Chinese ; Multiple myeloma ; Observational study ; Refractory ; Relapsed ; Response
刊名: ADVANCES IN THERAPY
发表日期: 2014-10-01
DOI: 10.1007/s12325-014-0159-z
卷: 31, 期:10, 页:1082-1094
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Medicine, Research & Experimental ; Pharmacology & Pharmacy
研究领域[WOS]: Research & Experimental Medicine ; Pharmacology & Pharmacy
关键词[WOS]: DEXAMETHASONE ; EPIDEMIOLOGY ; STRATEGIES ; PARADIGMS ; RISK
英文摘要:

Bortezomib, a novel proteasome inhibitor, is approved for the treatment of relapsed multiple myeloma (MM). Efficacy and safety of bortezomib is well known; however, it was necessary to validate the data in patients with different ethnic backgrounds. The efficacy and safety of bortezomib was assessed in patients from China with relapsed/refractory MM in a real-world scenario.

This prospective, non-interventional, observational study enrolled both male and female Chinese patients, aged a parts per thousand yen18 years and diagnosed with relapsed or refractory MM. Administration of intravenous bortezomib at 1.3 mg/m(2) was recommended twice a week for 2 weeks (days 1, 4, 8 and 11), followed by a 10-day rest period (maximum of 8 cycles) and a follow-up every 12 weeks for 3 years. Efficacy assessments included best response, objective response rate (ORR), time to response, duration of response, and overall survival. Safety was also assessed.

A total of 517 patients were enrolled with a median age of 58.7 years. Patients predominantly had immunoglobulin G type (46.2%) and stage III (47.8%) myeloma. Overall, 202 (42.3%) patients had partial response as best response, ORR was 88.9% and the proportion of patients exhibiting complete response was 24.7%. The median time to response observed was 27 (21-40) days. Median time to progression was 415 days and median overall survival was 475 days. Thrombocytopenia (14.4%) was the most common adverse event.

Bortezomib demonstrated clinical response in majority of patients and was well tolerated in this observational study in Chinese patients with relapsed/refractory MM.

语种: 英语
项目资助者: Xian-Janssen Pharmaceuticals, Beijing, China
WOS记录号: WOS:000344322000005
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/50086
Appears in Collections:北京大学第二临床医学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Hematol, Hangzhou, Zhejiang, Peoples R China
2.Second Mil Med Univ, Changzheng Hosp, Myeloma & Lymphoma Ctr, Shanghai, Peoples R China
3.Capital Med Univ, Beijing Chao Yang Hosp, Beijing, Peoples R China
4.Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China
5.China Med Univ, Shengjing Hosp, Shenyang, Liaoning, Peoples R China
6.Zhejiang Prov Tradit Chinese Med Hosp, Dept Hematol, Shenyang, Liaoning, Peoples R China
7.China Med Univ, Affiliated Hosp 1, Shenyang, Liaoning, Peoples R China
8.Xian Janssen Pharmaceut Co, Beijing, Peoples R China
9.Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai 200030, Peoples R China

Recommended Citation:
Lin, MaoFang,Hou, Jian,Chen, WenMing,et al. Improved Response Rates with Bortezomib in Relapsed or Refractory Multiple Myeloma: An Observational Study in Chinese Patients[J]. ADVANCES IN THERAPY,2014,31(10):1082-1094.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Lin, MaoFang]'s Articles
[Hou, Jian]'s Articles
[Chen, WenMing]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Lin, MaoFang]‘s Articles
[Hou, Jian]‘s Articles
[Chen, WenMing]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace